American Society of Hematology--51st annual meeting & exposition. Part 2.
The 51st Annual Meeting & Exposition of the American Society of Hematology, held in New Orleans, included topics covering new therapeutic developments in the field of hematology. This conference report highlights selected presentations on combination regimens for the treatment of multiple myeloma, selected kinase inhibitors and a recombinant HOXB4 protein. Investigational drugs discussed include SB-1518 (S*Bio Pte Ltd) and PF-2341066 (Pfizer Inc).
Shumoogam
Jaya
J
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. jaya.shumoogam@thomsonreuters.com
Beecher
Natasher
N
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D015507:Drugs, Investigational / Q000494:pharmacology*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
D015507:Drugs, Investigational; D047428:Protein Kinase Inhibitors